How Nerve-Released Peptides May Drive Airway Inflammation in Asthma and COPD
Sensory nerves in the airways release inflammatory neuropeptides like substance P and CGRP that amplify airway inflammation in animal models, but their role in human asthma and COPD remains unproven.
Quick Facts
What This Study Found
Neuropeptides — particularly tachykinins (substance P, neurokinin A) and calcitonin gene-related peptide (CGRP) — are released from sensory nerves in the airways through axon reflexes and local nerve activation. In rodent models, this neurogenic inflammation clearly contributes to responses against allergens, infections, and irritants. However, direct evidence for sensory neuropeptide involvement in human airway disease is lacking, and initial clinical studies using strategies to block neurogenic inflammation have not shown encouraging results.
Key Numbers
How They Did This
This is a narrative review by P.J. Barnes examining the evidence for neurogenic inflammation in airways across species. It covers in vitro and in vivo animal studies, human tissue data, and early clinical trial results targeting neuropeptide pathways in airway disease.
Why This Research Matters
Asthma and COPD affect hundreds of millions of people worldwide, and many patients remain poorly controlled on existing therapies. If neuropeptide-driven inflammation contributes to these diseases in humans, blocking it could provide new treatment options. This review is important because it honestly assesses both the promise of this pathway and the gap between compelling animal data and disappointing human results.
The Bigger Picture
Neurogenic inflammation represents a direct connection between the nervous system and immune-mediated airway disease. Understanding this neuro-immune crosstalk through neuropeptides has become increasingly important as the field recognizes that asthma and COPD are not purely immune-driven conditions. The challenges described in this review — the species differences between rodents and humans — remain relevant to current neuropeptide research.
What This Study Doesn't Tell Us
This is a 2001 review and reflects the state of knowledge at that time. The author notes that direct evidence for neuropeptide involvement in human airway disease was limited and clinical trials had been negative. Subsequent research has provided some additional insights but the fundamental translation gap from rodent to human airway neurogenic inflammation persists.
Questions This Raises
- ?Would targeting neuropeptide pathways in severe asthma or COPD (rather than mild disease) reveal a meaningful clinical effect?
- ?Do CGRP-targeting therapies developed for migraine have any measurable effects on airway inflammation?
- ?Why is neurogenic inflammation so prominent in rodent airways but apparently less important in human airways?
Trust & Context
- Key Stat:
- Animal vs. human gap Neurogenic airway inflammation is well-established in rodents but clinical trials blocking neuropeptides in human asthma have not been encouraging
- Evidence Grade:
- This is a narrative review summarizing evidence from animal studies, human tissue experiments, and early clinical trials. It represents expert synthesis rather than new primary data.
- Study Age:
- Published in 2001 by a leading respiratory pharmacologist. While older, it provides foundational context for understanding neuropeptide involvement in airway disease. The species-translation challenge it describes remains relevant today.
- Original Title:
- Neurogenic inflammation in the airways.
- Published In:
- Respiration physiology, 125(1-2), 145-54 (2001)
- Authors:
- Barnes, P J
- Database ID:
- RPEP-00646
Evidence Hierarchy
Frequently Asked Questions
What is neurogenic inflammation in the airways?
It's a process where sensory nerves in the airways release inflammatory peptides (like substance P and CGRP) in response to irritants, allergens, or infections. These peptides cause swelling, mucus production, and blood vessel leakage — amplifying the inflammatory response.
Why haven't neuropeptide-blocking treatments worked for asthma?
While neurogenic inflammation is clearly important in rodent airways, the evidence that it drives human asthma is much weaker. Early clinical trials blocking these neuropeptide pathways showed no clear benefit, possibly because the role of neurogenic inflammation differs between species.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-00646APA
Barnes, P J. (2001). Neurogenic inflammation in the airways.. Respiration physiology, 125(1-2), 145-54.
MLA
Barnes, P J. "Neurogenic inflammation in the airways.." Respiration physiology, 2001.
RethinkPeptides
RethinkPeptides Research Database. "Neurogenic inflammation in the airways." RPEP-00646. Retrieved from https://rethinkpeptides.com/research/barnes-2001-neurogenic-inflammation-in-the
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.